drugset / Trial / NCT06446531
Prevention of Progression of Prediabetes, Obesity and CV Risk
Phase 1
Recruiting
64 enrolled
The University of Texas Health Science Center at San Antonio
Baptist Health Foundation of San Antonio · collab
RandomizedParallel-groupSingle-blindTreatment
Summary
The investigators are studying how to help people with prediabetes (Pre-DM) and obesity. The goal is to use new and affordable treatments to bring blood sugar levels back to normal and help participants to lose weight. The investigators also want to reduce participants risk of heart problems. The study team will look at how these treatments affect metabolism and other body functions to help find new ways to treat diabetes and obesity in the future.
Timeline
- Start
- 2024-09-11
- Primary completion
- 2027-07
- Completion
- 2027-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Empagliflozin | Small molecule | 25 mg | Oral |
| Subject | Metformin | Small molecule | 2000 mg | Oral |
| Subject | Pioglitazone | Small molecule | 15 mg | Oral |
| Subject | Semaglutide | Peptide | 7 mg | Oral |